Nishant Gupta - Rare and Interstitial Lung Diseases Research
My clinical research program focuses on interstitial and rare lung diseases, especially diffuse cystic lung diseases such as lymphangioleiomyomatosis (LAM), Birt-Hogg-Dube syndrome (BHD), pulmonary Langerhans cell histiocytosis (PLCH), and Sjögren syndrome associated lung disease.
Areas of focus within these diseases include:
- Improve our understanding of the disease epidemiology and natural history.
- Define the burden and optimal management strategies for spontaneous pneumothoraces that are frequently associated with cystic lung diseases.
- Explore novel treatment options for these diseases
- Develop diagnostic, predictive and prognostic biomarkers
- Disseminate knowledge about these diseases in an effort to improve detection rates and reduce the delay in diagnosis experienced by patients with rare diseases.
Our upcoming Clinical Trial to Examine Drug Combination as Treatment for LAM Patients was reported in the Office of Public Relations.
Potential projects for students and fellows:
We have a database of the various interstitial and rare lung disease patients in the University of Cincinnati ILD clinic. Investigator-initiated proposals to answer specific questions can be performed on the database. In addition, we are a part of the NIH-sponsored Rare Lung Diseases Consortium, and can use this worldwide clinic network to conduct studies.
Clinical Research Trials:
- Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome
- Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis
- Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
- Recruiting soon: A randomized double blind placebo-controlled multicenter phase III trial of combined resveratrol and sirolimus in LAM (RESULT II)